Comparative Effectiveness studies

Our researchers compare the benefits and harms of various methods for the prevention, treatment, and delivery of care to determine what will work best for specific people or populations. We collaborate with the Center for Effectiveness & Safety Research, a national Kaiser Permanente network that addresses questions in comparative effectiveness and on the safety of drugs, devices, biologics, and care delivery strategies.

Archimedes IndiGO End-Stage Renal Disease Tool Development and Validation

Archimedes IndiGO will be used to predict outcomes for Chronic Kidney Disease and provide an interface for patient management. The accuracy of outcomes prediction will be tested in this study.

Principal Investigator:

Stephen F. Derose, MD, MSHS

Funding Source:

Kaiser Foundation Health Plan, Inc.

Funding Years:

2013 - 2015

ASCEND Clinical Trial

A clinical trial to study the efficacy of natalizumab on reducing disability progression in subjects with secondary progressive multiple sclerosis.

Principal Investigator:

Annette M. Langer-Gould, MD, PhD, MS

Funding Source:

Biogen Idec, Inc.

Funding Years:

2011 - 2016

Cholesterol-lowering medication as risk factors for amyotrophic lateral sclerosis

The primary objective of this study is to investigate whether the use of cholesterol-lowering medications increases the risk of developing ALS or influences the rate of disease progression among individuals who have ALS.

Principal Investigator:

Annette M. Langer-Gould, MD, PhD, MS

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2012 - 2013

Chronic Myelogenous Leukemia and Outcomes of Tyrosine Kinase Inhibitor Therapy

The aim of this investigation initiated retrospective cohort study are to examine long-term health effects in the cohort of CML and determine if health effects vary by drug adherence to TKIs.

Principal Investigator:

Reina Haque, PhD, MPH

Funding Source:

Novartis Pharmaceuticals Corporation

Funding Years:

2013 - 2018

Occurrence of Herpes Zoster Among Elderly Population 60 or More Years of Age: A Comparison Between Vaccinated and Unvaccinated Population

The specific aims of the study are to evaluate the incidence of HZ among elderly population 60 or more years of age who were either vaccinated or not vaccinated with the vaccine and to evaluate whether some potential chronic conditions would modify the effect of the vaccine. The additional aims are to compare the healthcare utilization between vaccinated HZ cases and unvaccinated HZ cases, to compare the incidence of stroke in one year after HZ episode between vaccinated HZ cases and unvaccinated HZ cases, and to compare the incidence of HZ between concomitant and sequential administration of PPV 23 and Zostavax.

Principal Investigator:

Hung Fu Tseng, PhD, MPH

Funding Source:

Centers for Disease Control and Prevention (CDC)

Funding Years:

2012

Optimizing Risk Stratification and Comparative Effectiveness Research for Atrial Fibrilliation

The major goals of this project was to develop a collaboration of population-based researchers as well as a research platform using a contemporary cohort of about 40,000 adults with atrial fibrillation to improve comparative effectiveness studies, risk stratification of outcomes and the planning and conduct of future observational studies and randomized trials for atrial fibrillation.

Site Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

National Heart, Lung, and Blood Institute (NHLBI)

Funding Years:

2009 - 2012

Real World Effectiveness and Economic Impact of Subcutaneous Methotrexate compared to Oral Methotrexate Treatment for Rheumatoid Arthritis

This prospective study will evaluate the real-world effectiveness of subcutaneous vs. oral methotrexate treatment on disease activity and functional status of rheumatoid arthritis patients. We will also evaluate effectiveness on patient centered outcomes, treatment adherence, cost, and work productivity. Lastly, using a discrete choice experiment, we will estimate patient’s valuation of these outcomes and their willingness to pay.

Principal Investigator:

Aniket A. Kawatkar, PhD, MS

Funding Source:

Medac Pharma, Inc.

Funding Years:

2016

Skeletal Outcomes in Primary Hyperparathyroidism

The aim of the study is to retrospectively compare fracture rates and BMD changes in patients with PHPT who have received the following types of treatment: observation, bisphosphonate therapy, surgery, or both surgery and bisphosphonate therapy.

Principal Investigator:

Annette L. Adams, PhD, MPH

Funding Source:

University of California, Los Angeles (UCLA)

Funding Years:

2013 - 2019

The Comparative effectiveness of Warfarin and New Oral Anticoagulants for the Extended Treatment of Venous Thromboembolism

The overall goal of this project is to provide information on the benefits and harms comparing different treatment options for the extended treatment of VTE, information that can be used by clinicians and patients in deciding on the optimal treatment strategy.

Principal Investigator:

Kristi Reynolds, PhD, MPH

Funding Source:

Patient-Centered Outcomes Research Institute (PCORI)

Funding Years:

2016 - 2020

Use of Multiple Biomarkers with the Risk of Ovarian Cancer Algorithm (ROCA) for Early Detection of Ovarian Cancer in Female Carriers of BRCA1 and BRCA2 mutations

The goal of this prospective recruitment study is to determine if ovarian cancer screening is enhanced by more frequent biomarker testing (CA125 & HE4) versus usual testing frequency in women with BRCA1/2 mutations.

Principal Investigator:

Reina Haque, PhD, MPH

Funding Source:

Garfield Memorial Fund

Funding Years:

2016 - 2019